Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Ekaterina Poznyak"'
Autor:
Elena Koryagina, Irina Zotova, Elza Lomaia, Natalia Ilina, Vasiliy Shuvaev, Andrey Zaritskey, Zvenyslava Masliak, Irina Dyagil, Natalia Lazorko, Natalia Babkina, Irina Dmitrenko, T. Perekhrestenko, Elena Machulaitene, Svetlana Stepanova, Ekaterina Poznyak, Elena Usacheva, Kudrat Abdulkadirov, Irina Martinkevich, Eugenia Sbityakova, Ekaterina Romanova, Alla Abdulkadirova, Elena Goryunova, Maria Ivanova, Vera Udalieva, Tatiana Shneider
Publikováno v:
Blood. 118:4452-4452
Abstract 4452 Imatinib (IM) is now used world-wide as a first line chronic myeloid leukemia (CML) treatment. Although some time lack may exist between diagnosis and IM treatment. Earlier (Blood 2009, 114: Abstract 4278) we have shown that in CML chro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ddb01716cabed8d713333cbe913c4f27
https://doi.org/10.1182/blood.v118.21.4452.4452
https://doi.org/10.1182/blood.v118.21.4452.4452
Autor:
Dgariyat Shikhbabaeva, Elza Lomaia, Elena Usacheva, Ekaterina Romanova, Elena Machulaitene, Natalia Ilina, Irina Martynkevich, Alla Abdulkadyrova, Vasiliy Shuvaev, Evgenia Salamatova, Kudrat Abdulkadyrov, Irina Zotova, Tatiana Shneider, Vera Udalieva, Ekaterina Poznyak, Maria Ivanova, Natalia Lazorko, Elena Koryagina, Svetlana Stepanova, Andrey Zaritskey
Publikováno v:
Blood. 116:4476-4476
Abstract 4476 At present, the main goal of chronic myeloid leukemia (CML) therapy is to obtain complete cytogenetic response (CCyR) which is strongly associated with patient's survival. The second main factor for good prognosis after CCyR achievement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::76be59190c6a2d4e5ea90a0bae96377c
https://doi.org/10.1182/blood.v116.21.4476.4476
https://doi.org/10.1182/blood.v116.21.4476.4476
Autor:
Elena Usacheva, Vasiliy Shuvaev, Elena Goryunova, Svetlana Stepanova, Ekaterina Romanova, Kudrat Abdulkadirov, Alla Abdulkadirova, Tatiana Shneider, Irina Zotova, Elena Machulaitene, Andrey Zaritskey, Ekaterina Poznyak, Eugenia Salamatova, Vera Udalieva, Elza Lomaia, Elena Koryagina, Irina Martinkevich, Natalia Ilina, Natalija Lazorko
Publikováno v:
Blood. 114:4288-4288
Abstract 4288 Resistance to imatinib could be overcome by new generations of TKIs. Data about the efficacy of second line TKI treatment may help to create a system for prognosing the duration of 2nd line TKI treatment and time of switching from secon
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41eb1bf557e81ebcbe4490ee49b24c88
https://doi.org/10.1182/blood.v114.22.4288.4288
https://doi.org/10.1182/blood.v114.22.4288.4288
Autor:
Natalia Ilina, Natalija Lazorko, Elena Goryunova, Irina Zotova, Vasiliy Shuvaev, Elza Lomaia, Tatiana Shneider, Elena Koryagina, Vera Udalieva, Eugenia Salamatova, Elena Machulaitene, Kudrat Abdulkadirov, Elena Usacheva, Irina Martinkevich, Ekaterina Romanova, Alla Abdulkadirova, Andrey Zaritskey, Svetlana Stepanova, Ekaterina Poznyak
Publikováno v:
Blood. 114:4278-4278
Abstract 4278 Imatinib(IM) has become the “gold standard” for the treatment of CML CP. In clinical trials the majority of pts obtain complete hematologic (CHR) and complete cytogenetic (CCyR) responses. The aim of the study was to evaluate the re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5f727315554bec8281b578aceac326d7
https://doi.org/10.1182/blood.v114.22.4278.4278
https://doi.org/10.1182/blood.v114.22.4278.4278